These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33914382)

  • 21. Heterogeneity in Positive Predictive Value of RAS Mutations in Cytologically Indeterminate Thyroid Nodules.
    Nabhan F; Porter K; Lupo MA; Randolph GW; Patel KN; Kloos RT
    Thyroid; 2018 Jun; 28(6):729-738. PubMed ID: 29665745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The first Canadian experience with the Afirma® gene expression classifier test.
    Kay-Rivest E; Tibbo J; Bouhabel S; Tamilia M; Leboeuf R; Forest VI; Hier MP; Savoury L; Payne RJ
    J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):25. PubMed ID: 28372589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Genetics Augment Cytopathologic Evaluation and Surgical Planning of Pediatric Thyroid Nodules.
    Spaulding SL; Maayah M; Dinauer CA; Prasad M; Darbinyan A; Morotti R; Christison-Lagay ER
    J Pediatr Surg; 2024 May; 59(5):975-980. PubMed ID: 38246817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilities of
    Guan H; Toraldo G; Cerda S; Godley FA; Rao SR; McAneny D; Doherty G; Braverman L; Lee SL
    Thyroid; 2020 Apr; 30(4):536-547. PubMed ID: 31996097
    [No Abstract]   [Full Text] [Related]  

  • 25. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
    Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
    Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
    Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
    Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
    Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
    Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
    [No Abstract]   [Full Text] [Related]  

  • 28. Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
    Chiosea S; Hodak SP; Yip L; Abraham D; Baldwin C; Baloch Z; Gulec SA; Hannoush ZC; Haugen BR; Joseph L; Kargi AY; Khanafshar E; Livhits MJ; McIver B; Patel K; Patel SG; Randolph GW; Shaha AR; Sharma J; Stathatos N; van Zante A; Carty SE; Nikiforov YE; Nikiforova MN
    J Clin Endocrinol Metab; 2023 Oct; 108(11):2999-3008. PubMed ID: 37071871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy.
    Sacks WL; Bose S; Zumsteg ZS; Wong R; Shiao SL; Braunstein GD; Ho AS
    Cancer Cytopathol; 2016 Oct; 124(10):722-728. PubMed ID: 27347838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules.
    Marcadis AR; Valderrabano P; Ho AS; Tepe J; Swartzwelder CE; Byrd S; Sacks WL; Untch BR; Shaha AR; Xu B; Lin O; Ghossein RA; Wong RJ; Marti JL; Morris LGT
    Surgery; 2019 Jan; 165(1):17-24. PubMed ID: 30360906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Health Care Setting.
    Chen T; Gilfix BM; Rivera J; Sadeghi N; Richardson K; Hier MP; Forest VI; Fishman D; Caglar D; Pusztaszeri M; Mitmaker EJ; Payne RJ
    Thyroid; 2020 Sep; 30(9):1280-1287. PubMed ID: 32242511
    [No Abstract]   [Full Text] [Related]  

  • 32. Diagnostic utility of fine needle aspiration cytology in pediatric thyroid nodules based on Bethesda Classification.
    Jiang W; Phillips SA; Newbury RO; Naheedy JH; Newfield RS
    J Pediatr Endocrinol Metab; 2021 Apr; 34(4):449-455. PubMed ID: 33629571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.
    Nikiforova MN; Lepe M; Tolino LA; Miller ME; Ohori NP; Wald AI; Landau MS; Kaya C; Malapelle U; Bellevicine C; Troncone G; Nikiforov YE; Baloch Z
    Cancer Cytopathol; 2021 Jan; 129(1):33-42. PubMed ID: 32697051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic performance of the second-generation molecular tests in the assessment of indeterminate thyroid nodules: A systematic review and meta-analysis.
    Lee E; Terhaar S; McDaniel L; Gorelik D; Gerhard E; Chen C; Ma Y; Joshi AS; Goodman JF; Thakkar PG
    Am J Otolaryngol; 2022; 43(3):103394. PubMed ID: 35241290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ThyroSeq v2 Testing: Impact on Cytologic Diagnosis, Management, and Cost of Care in Patients with Thyroid Nodule.
    Fazeli SR; Zehr B; Amraei R; Toraldo G; Guan H; Kindelberger D; Lee S; Cerda S
    Thyroid; 2020 Oct; 30(10):1528-1534. PubMed ID: 32349630
    [No Abstract]   [Full Text] [Related]  

  • 36. Correlation of ThyroSeq Results with Surgical Histopathology in Cytologically Indeterminate Thyroid Nodules.
    Chin PD; Zhu CY; Sajed DP; Fishbein GA; Yeh MW; Leung AM; Livhits MJ
    Endocr Pathol; 2020 Dec; 31(4):377-384. PubMed ID: 32671653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
    Jug RC; Datto MB; Jiang XS
    Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses.
    Rossi M; Lupo S; Rossi R; Franceschetti P; Trasforini G; Bruni S; Tagliati F; Buratto M; Lanza G; Damiani L; Degli Uberti E; Zatelli MC
    Endocrine; 2017 Jul; 57(1):98-107. PubMed ID: 27623969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving Malignancy Prediction in AUS/FLUS Pediatric Thyroid Nodules with the Aid of Ultrasound.
    Arora S; Khoury J; Trout AT; Chuang J
    Horm Res Paediatr; 2020; 93(4):239-244. PubMed ID: 32894855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indeterminate nodules by the Bethesda system for reporting thyroid cytopathology in Israel: Frequency, and risk of malignancy after reclassification of follicular thyroid neoplasm with papillary-like features.
    Rosenblum RC; Shtabsky A; Marmor S; Trejo L; Yaish I; Barnes S; Yehuda M; Stern N; Silman Z; Tordjman KM
    Eur J Surg Oncol; 2019 Jul; 45(7):1182-1187. PubMed ID: 30928335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.